bcr-abl imatinib
The treatment of CML was revolutionized by the introduction of imatinib mesylate (IM, Gleevec), a BCR-ABL tyrosine kinase inhibitor (TKI). The clinical use of ... ,跳到 Imatinib (STI571) - Imatinib (Gleevec) was discovered in 1992 and is regarded as ... Bcr-Abl tyrosine kinase inhibitor to be used in the treatment of ... , This is the first report describing a new BCR-ABL kinase domain mutation—V280G—that might be associated with resistance to imatinib., Mutations in the drug binding region of BCR-ABL lead to imatinib resistance during the management of chronic myeloid leukemia (CML).,Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia ... , In chronic myeloid leukemia (CML), BCR/ABL-mediated oncogenic signaling can be targeted with the BCR/ABL-inhibitors Imatinib, Nilotinib ...,跳到 Imatinib-Resistant Mutations - Over a third of CML patients develop a resistance to imatinib, due mainly to mutations within the Bcr-Abl kinase domain ... ,本疾病治療關鍵之突破是在1990年代末. 期，針對BCR-ABL融合基因酪氨酸激酶抑制劑. (tyrosine kinase inhibitor, TKI)的發展，第一個. 藥物即為imatinib mesylate， ... , Imatinib 是最早用來治療慢性骨髓性白血病的酪胺酸激酶抑制劑，但有些病人會 ... 關鍵字： 慢性骨髓性白血病、BCR-ABL 融合基因、酪胺酸激酶抑制 ...
| 相關軟體 PDF-XChange Viewer 資訊 | |
|---|---|
 bcr-abl imatinib 相關參考資料
BCR-ABL tyrosine kinase inhibitors in the treatment of ... - NCBI
The treatment of CML was revolutionized by the introduction of imatinib mesylate (IM, Gleevec), a BCR-ABL tyrosine kinase inhibitor (TKI). The clinical use of ... https://www.ncbi.nlm.nih.gov Bcr-Abl tyrosine-kinase inhibitor - Wikipedia
跳到 Imatinib (STI571) - Imatinib (Gleevec) was discovered in 1992 and is regarded as ... Bcr-Abl tyrosine kinase inhibitor to be used in the treatment of ... https://en.wikipedia.org BCR-ABL V280G Mutation, Potential Role in Imatinib ... - NCBI
This is the first report describing a new BCR-ABL kinase domain mutation—V280G—that might be associated with resistance to imatinib. https://www.ncbi.nlm.nih.gov Novel mutations in the kinase domain of BCR-ABL gene ...
Mutations in the drug binding region of BCR-ABL lead to imatinib resistance during the management of chronic myeloid leukemia (CML). https://www.ncbi.nlm.nih.gov The Bcr-Abl tyrosine kinase inhibitor imatinib and promising ...
Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia ... https://www.ncbi.nlm.nih.gov The BCRABL-inhibitors imatinib, nilotinib and dasatinib ...
In chronic myeloid leukemia (CML), BCR/ABL-mediated oncogenic signaling can be targeted with the BCR/ABL-inhibitors Imatinib, Nilotinib ... https://www.ncbi.nlm.nih.gov The Ins and Outs of Bcr-Abl Inhibition - NCBI
跳到 Imatinib-Resistant Mutations - Over a third of CML patients develop a resistance to imatinib, due mainly to mutations within the Bcr-Abl kinase domain ... https://www.ncbi.nlm.nih.gov 慢性骨髓性白血病之進步-治療及疾病監測 - 台灣內科醫學會
本疾病治療關鍵之突破是在1990年代末. 期，針對BCR-ABL融合基因酪氨酸激酶抑制劑. (tyrosine kinase inhibitor, TKI)的發展，第一個. 藥物即為imatinib mesylate， ... http://www.tsim.org.tw 藥學雜誌電子報128期
Imatinib 是最早用來治療慢性骨髓性白血病的酪胺酸激酶抑制劑，但有些病人會 ... 關鍵字： 慢性骨髓性白血病、BCR-ABL 融合基因、酪胺酸激酶抑制 ... http://jtp.taiwan-pharma.org.t |